Polatuzumab vedotin plus bendamustine and rituximab in patients
with relapsed/refractory diffuse large B-cell lymphoma in the
real world

J 2022

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA et. al.

Basic information

Original name

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

Authors

VODICKA, Prokop (203 Czech Republic), Katerina BENESOVA (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution), Vit PROCHAZKA (203 Czech Republic), David BELADA (203 Czech Republic), Heidi MOCIKOVA (203 Czech Republic), Katerina STEINEROVA (203 Czech Republic), Juraj DURAS (203 Czech Republic), Josef KARBAN (203 Czech Republic), Veronika HANACKOVA (203 Czech Republic), Alice SYKOROVA (203 Czech Republic), Ales OBR (203 Czech Republic) and Marek TRNENY (203 Czech Republic, guarantor)

Edition

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2022, 0902-4441

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.100

RIV identification code

RIV/00216224:14110/22:00128259

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/ejh.13784

UT WoS

000793085400001

Keywords in English

DLBCL; polatuzumab vedotin; real world

Abstract

V originále

Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. Methods We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). Results Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. Conclusion Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.

Citovat

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA, Heidi MOCIKOVA, Katerina STEINEROVA, Juraj DURAS, Josef KARBAN, Veronika HANACKOVA, Alice SYKOROVA, Ales OBR and Marek TRNENY. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2022, vol. 109, No 2, p. 162-165. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13784.

@article{2249571,
   author = {Vodicka, Prokop and Benesova, Katerina and Janíková, Andrea and Prochazka, Vit and Belada, David and Mocikova, Heidi and Steinerova, Katerina and Duras, Juraj and Karban, Josef and Hanackova, Veronika and Sykorova, Alice and Obr, Ales and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {2},
   doi = {http://dx.doi.org/10.1111/ejh.13784},
   keywords = {DLBCL; polatuzumab vedotin; real world},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ejh.13784},
   volume = {109},
   year = {2022}
}

TY  - JOUR
ID  - 2249571
AU  - Vodicka, Prokop - Benesova, Katerina - Janíková, Andrea - Prochazka, Vit - Belada, David - Mocikova, Heidi - Steinerova, Katerina - Duras, Juraj - Karban, Josef - Hanackova, Veronika - Sykorova, Alice - Obr, Ales - Trneny, Marek
PY  - 2022
TI  - Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
JF  - European Journal of Haematology
VL  - 109
IS  - 2
SP  - 162-165
EP  - 162-165
PB  - Wiley-Blackwell
SN  - 09024441
KW  - DLBCL
KW  - polatuzumab vedotin
KW  - real world
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ejh.13784
N2  - Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. Methods We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). Results Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. Conclusion Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.
ER  -

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA, Heidi MOCIKOVA, Katerina STEINEROVA, Juraj DURAS, Josef KARBAN, Veronika HANACKOVA, Alice SYKOROVA, Ales OBR and Marek TRNENY. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2022, vol.~109, No~2, p.~162-165. ISSN~0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13784.

Detailed Information on Publication Record